## CITATION REPORT List of articles citing

Enhanced brain amyloid-? clearance by rifampicin and caffeine as a possible protective mechanism against Alzheimerts disease

DOI: 10.3233/jad-2012-120319 Journal of Alzheimerts Disease, 2012, 31, 151-65.

**Source:** https://exaly.com/paper-pdf/54037481/citation-report.pdf

Version: 2024-04-23

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
119	LRP1 in brain vascular smooth muscle cells mediates local clearance of Alzheimer's amyloid-[] <b>2012</b> , 32, 16458-65		148
118	Cognitive enhancers (nootropics). Part 1: drugs interacting with receptors. <i>Journal of Alzheimer Disease</i> , <b>2012</b> , 32, 793-887	4.3	44
117	Neurovascular defects and faulty amyloid-lascular clearance in Alzheimer's disease. <i>Journal of Alzheimer</i> Disease, <b>2013</b> , 33 Suppl 1, S87-100	4.3	83
116	Role of ABC transporters in the pathogenesis of Alzheimer's disease. <b>2012</b> , 3, 820-31		94
115	Caffeine increases mitochondrial function and blocks melatonin signaling to mitochondria in Alzheimer's mice and cells. <b>2012</b> , 63, 1368-79		51
114	Oxysterols decrease apical-to-basolateral transport of Alþeptides via an ABCB1-mediated process in an in vitro Blood-brain barrier model constituted of bovine brain capillary endothelial cells. <b>2013</b> , 1517, 1-15		32
113	In vitro investigation of amyloid-Thepatobiliary disposition in sandwich-cultured primary rat hepatocytes. <b>2013</b> , 41, 1787-96		16
112	Cognitive enhancers (nootropics). Part 3: drugs interacting with targets other than receptors or enzymes. disease-modifying drugs. <i>Journal of Alzheimer</i> Disease, <b>2013</b> , 34, 1-114	4.3	15
111	Olive-oil-derived oleocanthal enhances Emmyloid clearance as a potential neuroprotective mechanism against Alzheimer's disease: in vitro and in vivo studies. <b>2013</b> , 4, 973-82		179
110	Coffea arabica. <b>2013</b> , 614-679		1
109	Peroxisome proliferator-activated receptors and Alzheimer's disease: hitting the blood-brain barrier. <b>2013</b> , 48, 438-51		33
108	Targeting ApoE4/ApoE receptor LRP1 in Alzheimer's disease. <b>2013</b> , 17, 781-94		27
107	Oatp1a4 and an L-thyroxine-sensitive transporter mediate the mouse blood-brain barrier transport of amyloid-peptide. <i>Journal of Alzheimer Disease</i> , <b>2013</b> , 36, 555-61	4.3	18
106	A lipoprotein receptor cluster IV mutant preferentially binds amyloid-land regulates its clearance from the mouse brain. <b>2013</b> , 288, 15154-66		29
105	The low-density lipoprotein receptor-related protein 1 and amyloid-Etlearance in Alzheimer's disease. <i>Frontiers in Aging Neuroscience</i> , <b>2014</b> , 6, 93	5-3	141
104	A proposed role for efflux transporters in the pathogenesis of hydrocephalus. <b>2014</b> , 55, 366-76		12
103	Modeling cerebrovascular pathophysiology in amyloid-Imetabolism using neural-crest-derived smooth muscle cells. <b>2014</b> , 9, 391-401		21

102	Amyloid In hereditary cerebral hemorrhage with amyloidosis-Dutch type. <b>2014</b> , 25, 641-51	20
101	The role of ryanodine receptor type 3 in a mouse model of Alzheimer disease. <b>2014</b> , 8, 230-42	46
100	Alzheimer's and ABC transportersnew opportunities for diagnostics and treatment. <b>2014</b> , 72 Pt A, 54-60	57
99	Effects of oxysterols on the blood-brain barrier: implications for Alzheimer's disease. <b>2014</b> , 446, 687-91	36
98	Differences in amyloid-delearance across mouse and human blood-brain barrier models: kinetic analysis and mechanistic modeling. <b>2014</b> , 79, 668-78	83
97	Pharmacogenomics of Alzheimer's disease: novel therapeutic strategies for drug development. <b>2014</b> , 1175, 323-556	50
96	Mixed oligomers and monomeric amyloid-Idisrupts endothelial cells integrity and reduces monomeric amyloid-Itransport across hCMEC/D3 cell line as an in vitro blood-brain barrier model. <b>2014</b> , 1842, 1806-15	36
95	PET radiotracers for imaging P-glycoprotein: the challenge for early diagnosis in AD. <b>2014</b> , 9, 38-42	6
94	LRP-1 polymorphism is associated with global and regional amyloid load in Alzheimer's Disease in humans in-vivo. <b>2014</b> , 4, 411-6	14
93	RIFAMPICIN: an antibiotic with brain protective function. <b>2014</b> , 107, 37-42	27
92	Dysfunctional Wnt/Etatenin signaling contributes to blood-brain barrier breakdown in Alzheimer's disease. <b>2014</b> , 75, 19-25	61
91	Herpes Simplex Virus Type 1 and Other Pathogens are Key Causative Factors in Sporadic Alzheimer's Disease. <i>Journal of Alzheimer</i> Disease, <b>2015</b> , 48, 319-53	139
90	Endothelial LRP1 transports amyloid-[11-42) across the blood-brain barrier. 2016, 126, 123-36	196
89	Association study in Alzheimer’s disease of single nucleotide polymorphisms implicated with coffee consumption. <b>2015</b> , 42, 69-73	3
88	Evidence against a role of P-glycoprotein in the clearance of the Alzheimer's disease All-42 peptides. <b>2015</b> , 20, 421-30	10
87	Regulation of ABC efflux transporters at blood-brain barrier in health and neurological disorders. <b>2015</b> , 1628, 298-316	132
86	Visualization of Time-Dependent Distribution of Rifampicin in Rat Brain Using MALDI MSI and Quantitative LCMS/MS. <b>2015</b> , 13, 277-84	24
85	Synthesis and P-glycoprotein induction activity of colupulone analogs. <b>2015</b> , 13, 5488-96	12

84	Opportunities in pharmacogenomics for the treatment of Alzheimer's disease. <b>2015</b> , 10, 229-252	18
83	Age-Related Decline in Brain and Hepatic Clearance of Amyloid-Beta is Rectified by the Cholinesterase Inhibitors Donepezil and Rivastigmine in Rats. <b>2015</b> , 6, 725-36	30
82	Extra-virgin olive oil attenuates amyloid-land tau pathologies in the brains of TgSwDI mice. <b>2015</b> , 26, 1479-90	60
81	GM1-Modified Lipoprotein-like Nanoparticle: Multifunctional Nanoplatform for the Combination Therapy of Alzheimer's Disease. <b>2015</b> , 9, 10801-16	75
80	Oleocanthal enhances amyloid-lælearance from the brains of TgSwDI mice and in vitro across a human blood-brain barrier model. <b>2015</b> , 6, 1849-59	101
79	In vitro discrimination of the role of LRP1 at the BBB cellular level: focus on brain capillary endothelial cells and brain pericytes. <b>2015</b> , 1594, 15-26	45
78	The role of cholesterol metabolism in Alzheimer's disease. <b>2015</b> , 51, 947-65	41
77	Design, synthesis and P-gp induction activity of aryl phosphonate esters: identification of tetraethyl-2-phenylethene-1,1-diyldiphosphonate as an orally bioavailable P-gp inducer. <b>2016</b> , 7, 1910-1915	6
76	Effects of transthyretin on thyroxine and Emyloid removal from cerebrospinal fluid in mice. <b>2016</b> , 43, 844-50	9
75	Vitamin D Supplementation Appears to Increase Plasma Allo in Vitamin D Insufficient Older Adults: A Pilot Randomized Controlled Trial. <i>Journal of Alzheimer</i> Disease, <b>2016</b> , 52, 843-7	19
74	Rifampicin is a candidate preventive medicine against amyloid-land tau oligomers. 2016, 139, 1568-86	72
73	Action of Caffeine as an Amyloid Inhibitor in the Aggregation of All 6-22 Peptides. <b>2016</b> , 120, 9019-33	35
72	The role of caffeine as an inhibitor in the aggregation of amyloid forming peptides: a unified molecular dynamics simulation and experimental study. <b>2016</b> , 6, 78548-78558	19
71	Transporters as Drug Targets in Neurological Diseases. <b>2016</b> , 100, 441-453	18
70	Functional induction of P-glycoprotein efflux pump by phenyl benzenesulfonamides: Synthesis and biological evaluation of T0901317 analogs. <b>2016</b> , 122, 744-755	5
69	Role of caffeine as an inhibitor in aggregation of hydrophobic molecules: A molecular dynamics simulation study. <b>2016</b> , 224, 930-939	4
68	High-Throughput Screening for Identification of Blood-Brain Barrier Integrity Enhancers: A Drug Repurposing Opportunity to Rectify Vascular Amyloid Toxicity. <i>Journal of Alzheimer</i> Disease, <b>2016</b> , 4.3 53, 1499-516	31
67	Pharmacogenetic considerations in the treatment of Alzheimer's disease. <b>2016</b> , 17, 1041-74	31

66	Apolipoprotein E as a Therapeutic Target in Alzheimer's Disease: A Review of Basic Research and Clinical Evidence. <b>2016</b> , 30, 773-89	66
65	The role of the low-density lipoprotein receptor-related protein 1 (LRP-1) in regulating blood-brain barrier integrity. <b>2016</b> , 27, 623-34	36
64	Role of P-glycoprotein in mediating rivastigmine effect on amyloid-Drain load and related pathology in Alzheimer's disease mouse model. <b>2016</b> , 1862, 778-787	40
63	Neuroprotective Effects of Extra-Virgin Olive Oil and its Components in Alzheimer's Disease. <b>2017</b> , 299-315	1
62	Amylin Enhances Amyloid-IPeptide Brain to Blood Efflux Across the Blood-Brain Barrier. <i>Journal of Alzheimer</i> Disease, <b>2017</b> , 56, 1087-1099	15
61	The neuroprotective effects of caffeine in neurodegenerative diseases. <b>2017</b> , 23, 272-290	116
60	Endothelial LRP1 - A Potential Target for the Treatment of Alzheimer's Disease: Theme: Drug Discovery, Development and Delivery in Alzheimer's Disease Guest Editor: Davide Brambilla. <b>2017</b> , 34, 2637-2651	25
59	Preventive Effect of Rifampicin on Alzheimer Disease Needs at Least 450 mg Daily for 1 Year: An FDG-PET Follow-Up Study. <b>2017</b> , 7, 204-214	15
58	⊞ynuclein aggregation modulation: an emerging approach for the treatment of Parkinson's disease. <b>2017</b> , 9, 1039-1053	21
57	Crocus sativus Extract Tightens the Blood-Brain Barrier, Reduces Amyloid Load and Related Toxicity in 5XFAD Mice. <b>2017</b> , 8, 1756-1766	44
56	Therapeutic role of rifampicin in Alzheimer's disease. <b>2018</b> , 72, 152-159	33
55	Dual targeting agents for Alplaque/P-glycoprotein and Alplaque/nicotinic acetylcholine 42* receptors-potential approaches to facilitate Alplaque removal in Alzheimer's disease brain. 2018, 27, 1634-1646	4
54	Normal macromolecular clearance out of the ventricles is delayed in hydrocephalus. 2018, 1678, 337-355	12
53	Protective Effect of Hyperforin on Amyloid Protein Induced Apoptosis in PC12 Cells and Colchicine Induced Alzheimer's Disease: An Anti-oxidant and Anti-inflammatory Therapy. <b>2018</b> , 67, 1443-1453	9
52	Neuroinflammatory Cytokines Induce Amyloid Beta Neurotoxicity through Modulating Amyloid Precursor Protein Levels/Metabolism. <b>2018</b> , 2018, 3087475	49
51	Pharmacoepigenomic Interventions as Novel Potential Treatments for Alzheimer's and Parkinson's Diseases. <i>International Journal of Molecular Sciences</i> , <b>2018</b> , 19,	29
50	Rifampicin ameliorates lithium-pilocarpine-induced seizures, consequent hippocampal damage and memory deficit in rats: Impact on oxidative, inflammatory and apoptotic machineries. <b>2018</b> , 156, 431-443	25
49	Modulation of the ATP-Binding Cassette B1 Transporter by Neuro-Inflammatory Cytokines: Role in the Pathogenesis of Alzheimer's Disease. <b>2018</b> , 9, 658	12

48	ABCA7 Downregulation Modifies Cellular Cholesterol Homeostasis and Decreases Amyloid- Peptide Efflux in an in vitro Model of the Blood-Brain Barrier. <i>Journal of Alzheimer</i> Disease, <b>2018</b> , 64, 1195-1211	4.3	19
47	Promoting the clearance of neurotoxic proteins in neurodegenerative disorders of ageing. <b>2018</b> , 17, 660-688		232
46	Epigenetic Drug Discovery for Alzheimer Disease. 2018, 453-495		7
45	Age Modulates the Association of Caffeine Intake With Cognition and With Gray Matter in Elderly Diabetics. <b>2019</b> , 74, 683-688		6
44	Apolipoprotein E and Alzheimer disease: pathobiology and targeting strategies. 2019, 15, 501-518		322
43	Granisetron Alleviates Alzheimer's Disease Pathology in TgSwDI Mice Through Calmodulin-Dependent Protein Kinase II/cAMP-Response Element Binding Protein Pathway. <i>Journal of Alzheimer</i> Disease, <b>2019</b> , 72, 1097-1117	4.3	3
42	Recent Expansions on Cellular Models to Uncover the Scientific Barriers Towards Drug Development for Alzheimer's Disease. <b>2019</b> , 39, 181-209		32
41	Multi-faceted therapeutic strategy for treatment of Alzheimer's disease by concurrent administration of etodolac and £ocopherol. <b>2019</b> , 125, 123-134		13
40	Natural Compounds for Alzheimer's Disease Therapy: A Systematic Review of Preclinical and Clinical Studies. <i>International Journal of Molecular Sciences</i> , <b>2019</b> , 20,	6.3	85
39	Interaction of natural compounds with biomembrane models: A biophysical approach for the Alzheimer's disease therapy. <b>2019</b> , 180, 83-92		20
38	Plasma Rich in Growth Factors (PRGF) Disrupt the Blood-Brain Barrier Integrity and Elevate Amyloid Pathology in the Brains of 5XFAD Mice. <i>International Journal of Molecular Sciences</i> , <b>2019</b> , 20,	6.3	4
37	The A-B-C of small-molecule ABC transport protein modulators: From inhibition to activation-a case study of multidrug resistance-associated protein 1 (ABCC1). <b>2019</b> , 39, 2031-2081		10
36	Somatostatin Maintains Permeability and Integrity of Blood-Brain Barrier in EAmyloid Induced Toxicity. <b>2019</b> , 56, 292-306		7
35	An outlook on the role of decaffeinated coffee in neurodegenerative diseases. <b>2020</b> , 60, 760-779		20
34	Imaging P-Glycoprotein Induction at the Blood-Brain Barrier of a EAmyloidosis Mouse Model with C-Metoclopramide PET. <b>2020</b> , 61, 1050-1057		10
33	The Use of Antimicrobial and Antiviral Drugs in Alzheimer's Disease. <i>International Journal of Molecular Sciences</i> , <b>2020</b> , 21,	6.3	10
32	Brain Distribution of Dual ABCB1/ABCG2 Substrates Is Unaltered in a Beta-Amyloidosis Mouse Model. <i>International Journal of Molecular Sciences</i> , <b>2020</b> , 21,	6.3	3
31	Molecular Insight into the Therapeutic Promise of Targeting for Alzheimer's Disease. <b>2020</b> , 2020, 5086	250	28

30	Long-term exposure to constant light induces dementia, oxidative stress and promotes aggregation of sub-pathological Alln Wistar rats. <b>2020</b> , 192, 172892		6
29	Thermodynamic insights into molecular interactions of sodium lauryl sulfate (SLS) with caffeine and theophylline in aqueous media at different temperatures. <b>2020</b> , 305, 112776		2
28	Ketone Bodies Promote Amyloid-IClearance in a Human in Vitro Blood-Brain Barrier Model. <i>International Journal of Molecular Sciences</i> , <b>2020</b> , 21,	6.3	18
27	Dysfunction of ABC transporters at the blood-brain barrier: Role in neurological disorders. <b>2020</b> , 213, 107554		38
26	Rifampicin Suppresses Amyloid-l'Accumulation Through Enhancing Autophagy in the Hippocampus of a Lipopolysaccharide-Induced Mouse Model of Cognitive Decline. <i>Journal of Alzheimer</i> Disease, <b>2021</b> , 79, 1171-1184	4.3	4
25	APOE and Alzheimer's Disease: From Lipid Transport to Physiopathology and Therapeutics. <b>2021</b> , 15, 630502		29
24	Rifampicin ameliorates lipopolysaccharide-induced cognitive and motor impairments via inhibition of the TLR4/MyD88/NF- <b>B</b> signaling pathway in mice. <b>2021</b> , 43, 358-371		1
23	Role of ABCA7 in Human Health and in Alzheimer's Disease. <i>International Journal of Molecular Sciences</i> , <b>2021</b> , 22,	6.3	10
22	Bioactive Compounds and Traditional Herbal Medicine: Promising Approaches for the Treatment of Dementia. <b>2021</b> , 11, 1-14		7
21	Anti-Alzheimer's Molecules Derived from Marine Life: Understanding Molecular Mechanisms and Therapeutic Potential. <b>2021</b> , 19,		10
20	Potential Virus Involvement in Alzheimer's Disease: Results from a Phase IIa Trial Evaluating Apovir, an Antiviral Drug Combination. <i>Journal of Alzheimer</i> Disease Reports, <b>2021</b> , 5, 413-431	3.3	1
19	Tailoring of P-glycoprotein for effective transportation of actives across blood-brain-barrier. <i>Journal of Controlled Release</i> , <b>2021</b> , 335, 398-407	11.7	5
18	Impact of age, hypercholesterolemia, and the vitamin D receptor on brain endogenous Emyloid peptide accumulation in mice. <i>Biopharmaceutics and Drug Disposition</i> , <b>2021</b> , 42, 372-388	1.7	3
17	Blood-Brain Barrier Disruption Increases Amyloid-Related Pathology in TgSwDI Mice. <i>International Journal of Molecular Sciences</i> , <b>2021</b> , 22,	6.3	4
16	Contributions of Drug Transporters to Blood-Brain Barriers. <i>Advances in Experimental Medicine and Biology</i> , <b>2019</b> , 1141, 407-466	3.6	6
15	Behavioral and pathophysiological outcomes associated with caffeine consumption and repetitive mild traumatic brain injury (RmTBI) in adolescent rats. <i>PLoS ONE</i> , <b>2017</b> , 12, e0187218	3.7	17
14	Effect of mouse strain as a background for Alzheimer's disease models on the clearance of amyloid-\( \Pi \) Journal of Systems and Integrative Neuroscience, <b>2016</b> , 2, 135-140	2.9	7
13	Protective Effects of the Caffeine Against Neurodegenerative Diseases. <i>Current Medicinal Chemistry</i> , <b>2019</b> , 26, 5137-5151	4.3	12

12	Neuroprotective effects of some epigenetic modifying drugs' on Chlamydia pneumoniae-induced neuroinflammation: A novel model. <i>PLoS ONE</i> , <b>2021</b> , 16, e0260633	3.7	1
11	Compromised Astrocyte Swelling/Volume Regulation in the Hippocampus of the Triple Transgenic Mouse Model of Alzheimer's Disease <i>Frontiers in Aging Neuroscience</i> , <b>2021</b> , 13, 783120	5.3	O
10	A reappraisal on amyloid cascade hypothesis: the role of chronic infection in Alzheimer's disease <i>International Journal of Neuroscience</i> , <b>2022</b> , 1-19	2	О
9	Perspectives on the Role of as a Therapeutic Target for Alzheimer's Disease <i>Journal of Alzheimer</i> Disease Reports, <b>2021</b> , 5, 899-910	3.3	
8	Novel benzofurane carbonyl analogs of donepezil as acetylcholinesterase inhibitors. <i>Journal of Molecular Structure</i> , <b>2022</b> , 1264, 133193	3.4	O
7	Neuroprotective Effect of Caffeine in Alzheimer Disease. <i>Molecules</i> , <b>2022</b> , 27, 3737	4.8	1
6	BloodBrain barrier permeability in response to caffeine challenge. Magnetic Resonance in Medicine,	4.4	О
5	Targeted brain delivery of RVG29-modified rifampicin-loaded nanoparticles for Alzheimer's disease treatment and diagnosis.		1
4	TNF-land IL-1[Modulate Blood-Brain Barrier Permeability and Decrease Amyloid-[Peptide Efflux in a Human Blood-Brain Barrier Model. <b>2022</b> , 23, 10235		3
3	Polyunsaturated Fatty Acids Mend Macrophage Transcriptome, Glycome, and Phenotype in the Patients with Neurodegenerative Diseases, Including Alzheimer Disease. <b>2022</b> , 1-18		O
2	In Vitro Study of the Blood <b>B</b> rain Barrier Transport of Natural Compounds Recovered from Agrifood By-Products and Microalgae. <b>2023</b> , 24, 533		O
1	Imaging blood-brain barrier dysfunction: A state-of-the-art review from a clinical perspective. 15,		O